DelveInsight’s ‘Systemic Lupus Erythematosus Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Systemic Lupus Erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Systemic Lupus Erythematosus pipeline domain.
For Systemic Lupus Erythematosus emerging drugs, the Systemic Lupus Erythematosus pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report
- Over 60+ Systemic Lupus Erythematosus pipeline therapies are in various stages of development, and their anticipated acceptance in the Systemic Lupus Erythematosus market would significantly increase market revenue.
- Leading Systemic Lupus Erythematosus companies developing novel drug candidates to improve the Systemic Lupus Erythematosus treatment landscape include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and others.
- Promising Systemic Lupus Erythematosus pipeline therapies in various stages of development include TJ202, PF-06835375, Itolizumab, KPG 818, ICP-022, BOS161721, NKTR-358, ABBV-599, Deucravacitinib, SAR441344, BIIB059, Baricitinib, Obinutuzumab, LY3471851, TX200-TR101, Forigerimod, CS 12192, Zilucoplan, Ivarmacitinib, Research program: therapeutics, Solute carrier family 15 member 4 inhibitor, and others.
- In October 2022, Alpine Immune Sciences, Inc. announced that it would have poster presentations at upcoming scientific conferences for ALPN-303’s phase 1 study (RUBY-1).
- In October 2022, Aurinia Pharmaceuticals Inc. announced that data from multiple studies of LUPKYNIS® (voclosporin) would be presented at the American Society of Nephrology (ASN) Kidney Week 2022, which will be held November 3-6 in Orlando, Florida.
Request a sample and discover the recent breakthroughs happening SLE pipeline landscape in @ Systemic Lupus Erythematosus Pipeline Report
Systemic Lupus Erythematosus Overview
Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that is associated with significant morbidity and mortality. The loss of immunological tolerance against self-antigens is influenced by genetic, immunological, endocrine, and environmental factors, resulting in the formation of pathogenic autoantibodies that cause tissue damage via multiple mechanisms. Systemic Lupus Erythematosus pathogenesis is complex, and our understanding of SLE pathogenesis constantly evolves. When genetically susceptible individuals are exposed to environmental factors, a tolerance break occurs, resulting in the activation of autoimmunity.
Systemic Lupus Erythematosus Pipeline Analysis: Drug Profile
Obinutuzumab: Roche
Obinutuzumab (Gazyva/Gazyvaro) is a monoclonal antibody that has been engineered to bind to CD20, a protein expressed on certain B cells but not on stem or plasma cells. Gazyva/Gazyvaro is intended to attack and destroy specific B-cells both directly and in collaboration with the body’s immune system. In the EU and Switzerland, Gazyva is marketed as Gazyvaro. The drug is currently in Phase III development for the treatment of Systemic Lupus Erythematosus.
Ianalumab: Novartis
Ianalumab (VAY736) is a fully human monoclonal anti-B-cell activating factor (BAFF) receptor antibody designed for direct ADCC-mediated B-cell depletion. The drug is currently in Phase II clinical trials for the treatment of SLE. Other Novartis-led trials are investigating Ianalumab in chronic lymphocytic leukemia, rheumatoid arthritis, and idiopathic pulmonary fibrosis, among other indications.
Systemic Lupus Erythematosus Pipeline Therapies and Key Companies
- TJ202: I-Mab Biopharma
- Forigerimod: ImmuPharma
- Obinutuzumab: Hoffman-La-Roche
- Baricitinib: Eli Lilly and Company
- BIIB059: Biogen
- SAR441344: Sanofi
- Deucravacitinib: Bristol Myers Squibb
- ABBV-599: AbbVie
- NKTR-358: Nektar Therapeutics
- BOS161721: Boston Pharmaceuticals
- ICP-022: InnoCare Pharma
- KPG 818: Kangpu Biopharmaceuticals
Learn more about the SLE emerging pipeline therapies @Systemic Lupus Erythematosus Clinical Trials
Systemic Lupus Erythematosus Pipeline Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- By Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
Scope of the Systemic Lupus Erythematosus Pipeline Report
- Coverage: Global
- Key Systemic Lupus Erythematosus Companies: AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and others.
- Key Systemic Lupus Erythematosus Pipeline Therapies: TJ202, PF-06835375, Itolizumab, KPG 818, ICP-022, BOS161721, NKTR-358, ABBV-599, Deucravacitinib, SAR441344, BIIB059, Baricitinib, Obinutuzumab, LY3471851, TX200-TR101, Forigerimod, CS 12192, Zilucoplan, Ivarmacitinib, Research program: therapeutics, Solute carrier family 15 member 4 inhibitor, and others.
Dive deep into rich insights for SLE emerging therapies and assessment; visit @Systemic Lupus Erythematosus Emerging Therapies
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Overview |
| 4. | Pipeline Therapeutics |
| 5. | Late Stage Products (Phase III) |
| 6. | Mid Stage Products (Phase II) |
| 7. | Early Stage Products (Phase I/II) |
| 8. | Preclinical Stage Products |
| 9. | Discovery Stage Products |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Collaborations Assessment- Licensing / Partnering / Funding |
| 13. | Unmet Needs |
| 14. | Market Drivers and Barriers |
| 15. | Appendix |
| 16. | About DelveInsight |
For further information on the SLE current pipeline therapeutics, reach out @Systemic Lupus Erythematosus Therapeutics Assessment
Related Reports
Cutaneous Lupus Erythematosus Market
DelveInsight’s “Cutaneous Lupus Erythematosus – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, and others.
DelveInsight’s ‘Cervical Cancer – Market Insights, Epidemiology, and Market Forecast-2032’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others
Intratumoral Cancer Therapies Market
DelveInsight’s ‘Intratumoral Cancer Therapies – Market Insights, Epidemiology and Market Forecast—2032’ report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Takara Bio, NanOlogy, Istari Oncology, Moderna Therapeutics, Intensity Therapeutics, and several others.
DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like Bayer Health Care, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.
DelveInsight’s, “CAR-T – Pipeline Insights, 2022,” report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd., and others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Hemophilia A Market | Hemostasis Market | Peptic Ulcers Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187